Emerging technologies & innovation systems

A disruptive or path-breaking innovation can deliver remarkable advances in healthcare, agriculture, energy, transport and financial services but innovators in these areas are also faced with great uncertainty around the nature of future business models and value chains. Innogen offers new insights and methodological approaches for foresighting future business models and value chains in the context of an innovation ecosystem that can either support or constrain the eventual market availability of the technology. Innogen’s expertise lies in understanding, assessing and supporting this innovation-led growth.

Projects

Joyce Tait joins the Regulatory Horizons Council

16 September 2020

Innogen’s co-Director has been appointed as a member of the UK Government’s new Regulatory Horizons Council, an independent expert committee set up to provide impartial, expert advice on the regulatory reform required to support the rapid and safe introduction of new technologies.

Sir John Kingman reflects on his time as UKRI Chair

30 July 2021

At an event hosted by UK’s national academies on the 14th July, Sir John Kingman gave a talk on his experience as Chair of UKRI. Some of his comments on the need to improve links with industry and to reshape regulation in R&D-based sectors in ways that promote innovation, resonated with Innogen members who have expressed similar concerns for years.

Launching a series of ‘In Conversation’ events

7 February 2022

Over the coming months, Innogen researchers will be hosting and participating in ‘In Conversation’ events in which they will discuss some of their latest research and policy work.

In Conversation event: Why is drug R&D so much less efficient now than it was in 1950?

16 March 2023

On the 2nd of February, Dr Farah Huzair, Lecturer in Science, Technology and Innovation Studies, at The University of Edinburgh's School of Social and Political Sciences, and Dr Jack Scannell, CEO of Etheros Pharmaceuticals and Innogen Associate, discussed the reasons underlying the marked decline in drug R&D output efficiency since 1950 and ways to improve it.

Innogen Alumni, a blog post by Dave Wield

2 June 2025

If you are an Innogen Alumnus, or even if you are not, why don’t you check in and let us know what you are up to right now.